Ovarian cancer recurrence:is the definition of platinum resistance modified by PARPi and other intervening treatments?The evolving landscape in the management of platinum-resistant ovarian cancer
作者机构：Department of OncologyUniversity College London HospitalLondon NW12PGUnited Kingdom. UCL Cancer InstituteUniversity College LondonLondon WC1E 6DDUnited Kingdom.
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2022年第5卷第2期
页 面：424-435页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：AstraZeneca Merck/MSD
主 题：Platinum resistance PARP inhibitors VEGF inhibitors immune checkpoint inhibitors DNA damage response
摘 要：Definitions of platinum resistance have been questioned and changed over the last five years,even though no predictive biomarker of resistance *** have sculpted how we approach platinum retreatment and,consequently,how we devise new treatment strategies for those patients with tumour progression on platinum ***-non-eligible ovarian cancer is treated with single-agent non-platinum *** bevacizumab can be added to chemotherapy,progression-free survival improves *** patients with a BRCA mutation,PARP inhibitor monotherapy is an option compared to *** is currently no clearly identified role for immune-checkpoint inhibition in this patient *** review describes some of the challenges in treating patients with platinum resistance and suggests refinements in the selection of patients most likely to benefit from targeting a DNA damage response,angiogenesis or immune *** also describes novel agents of interest and possible mechanisms of the synergy of therapeutic combinations.
维普期刊数据库